EMEA-000367-PIP01-08-M08
Key facts
| Invented name |
Ruconest
|
| Active substance |
Conestat alfa
|
| Therapeutic area |
Other
|
| Decision number |
P/0343/2018
|
| PIP number |
EMEA-000367-PIP01-08-M08
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of hereditary angioedema
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Pharming Group N.V.
Tel. +31 715247400
E-mail: info@pharming.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-000367-PIP01-08-M08
|
| Compliance opinion date |
01/03/2019
|
| Compliance outcome |
positive
|